MAUNA KEA TECHNOLOGIES (EPA:MKEA) MAUNA KEA TECHNOLOGIES ANNOUNCES ITS 2015 FINANCIAL CALENDAR
Transparency directive : regulatory news
11/12/2014 17:45
Click here to download pdf version
PRESS RELEASEMAUNA KEA TECHNOLOGIES ANNOUNCES ITS 2015 FINANCIAL CALENDAR
PARIS, December 11, 2014 - Mauna Kea Technologies (NYSE Euronext: MKEA,
FR0010609263), leader in the optical biopsy market and developer of
Cellvizio(r), the fastest way to see cancer, announced today its schedule for
the publication of financial information for 2014.
Event Date *
2014 Full-Year Sales January 7, 2015
2014 Full-Year Results and
2015 First-Quarter Sales April 14, 2015
Annual General Meeting June 16, 2015
2015 First-Half Sales July 15, 2015
2015 First-Half Results September 9, 2015
2015 Third-Quarter Sales October 15, 2015
* Subject to modification. Press releases are published after market closes.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on leading
innovation in endomicroscopy and optical biopsy. The company designs, develops
and markets innovative tools to visualize and detect cell abnormalities in real
time during standard gastrointestinal and pulmonary endoscopy procedures. The
company's flagship product, Cellvizio(r), a probe needlebased Confocal Laser
Endomicroscopy (pCLE/nCLE) system, provides physicians and researchers with
high-resolution cellular imaging of internal tissues. Large-scale,
international, multi-center clinical trials have demonstrated Cellvizio's
ability to help physicians to more accurately detect early forms of diseases and
make immediate treatment decisions. Designed to help physicians in their
diagnoses, provide patients with better treatment and reduce hospital costs, the
Cellvizio system can be used with virtually any endoscope. Cellvizio has 510(k)
clearance from the United States Food and Drug Administration and CE Marking in
the European Union for use in the gastrointestinal tract and the urinary and
respiratory systems, for endoscopic exploration of the biliary and pancreatic
ducts and for fine-needle aspiration procedures. Cellvizio has also obtained
SFDA regulatory approval in China and MHLW approval in Japan.
For further information on Mauna Kea Technologies, visit www.maunakeatech.com
Madis Phileo
Press Relations
Marina Rosoff
Tel: +33 (0)6 71 58 00 34
maunakeatech@madisphileo.com
NewCap
Europe - Investor Relations
Florent Alba / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
maunakea@newcap.fr
Westwicke Partners
United States - Investor Relations
Mark Klausner
Tel.: +(443) 213-0500
maunakea@westwicke.com
MAUNA KEA TECHNOLOGIES's latest news
25/04/2024 20:50
02/11/2023 08:00
28/09/2023 08:00
19/09/2023 08:00
04/08/2023 08:00
26/04/2023 19:59
27/10/2022 18:02
26/07/2022 17:57
12/04/2022 18:05
09/02/2021 18:00
Other stories
16/05/2024 12:07
16/05/2024 10:10
16/05/2024 08:45
16/05/2024 12:07
16/05/2024 13:03
15/05/2024 15:04
16/05/2024 10:31
16/05/2024 12:05
16/05/2024 03:31
16/05/2024 13:04
16/05/2024 12:35
15/05/2024 22:38
16/05/2024 11:30
16/05/2024 09:46
16/05/2024 12:00
16/05/2024 12:56
16/05/2024 01:03
16/05/2024 00:23
16/05/2024 09:50
15/05/2024 19:00
16/05/2024 04:00
15/05/2024 21:30
16/05/2024 00:06
16/05/2024 00:59
16/05/2024 09:50
16/05/2024 01:44
16/05/2024 13:02
16/05/2024 12:32
16/05/2024 09:00
15/05/2024 18:55
16/05/2024 09:24
15/05/2024 22:40
15/05/2024 11:19
15/05/2024 15:00
16/05/2024 10:46
16/05/2024 09:00
16/05/2024 10:15
16/05/2024 12:03